Compare OVLY & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVLY | ZURA |
|---|---|---|
| Founded | 1990 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.9M | 252.9M |
| IPO Year | N/A | N/A |
| Metric | OVLY | ZURA |
|---|---|---|
| Price | $30.38 | $5.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 15.6K | ★ 467.0K |
| Earning Date | 01-23-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $79,783,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.58 | ★ N/A |
| Revenue Growth | ★ 2.98 | N/A |
| 52 Week Low | $22.70 | $0.97 |
| 52 Week High | $31.45 | $5.07 |
| Indicator | OVLY | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 58.71 | 76.58 |
| Support Level | $30.10 | $4.00 |
| Resistance Level | $31.45 | $4.44 |
| Average True Range (ATR) | 0.64 | 0.28 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 64.76 | 95.97 |
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.